Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis e virus infection in a haemodialysis patient

Nephrology Dialysis Transplantation

Volumn 25, Issue 8, 2010, Pages 2792-2795

  Kamar, Nassim ^a   Abravanel, Florence ^b   Garrouste, Cyril ^a,b   Cardeau Desangles, Isabelle ^a   Mansuy, Jean Michel ^b   Weclawiak, Hugo ^a   Izopet, Jacques ^b   Rostaing, Lionel ^a,b  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

Author keywords

chronic hepatitis; haemodialysis; hepatitis E virus; pegylated interferon

Indexed keywords

CREATININE; CYCLOSPORIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIVER ENZYME; MYCOPHENOLIC ACID; PEGINTERFERON ALPHA2A; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VIRUS RNA; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ACUTE GRAFT REJECTION; ADULT; ALPORT SYNDROME; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC HEPATITIS E; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FECES; FOLLOW UP; GENOTYPE; HEMODIALYSIS; HEPATITIS E; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; CHRONIC DISEASE; DOSE RESPONSE; HEPATITIS E VIRUS; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; NEPHRITIS, HEREDITARY; OPPORTUNISTIC INFECTIONS; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATITIS E; HEPATITIS E VIRUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; NEPHRITIS, HEREDITARY; OPPORTUNISTIC INFECTIONS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 77954791748     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq282     Document Type: Article

References (19)

1. Dalton HR, Bendall R, Ijaz S et al. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 2008; 8: 698-709
2. Kamar N, Selves J, Mansuy JM et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358: 811-817
3. Ollier L, Tieulie N, Sanderson F et al. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 2009; 150: 430-431
4. Dalton HR, Bendall R, Keane F et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009; 361: 1025-1027
5. Gerolami R, Moal V, Colson P. Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008; 358: 859-860
6. Kamar N, Mansuy JM, Cointault O et al. Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients. Am J Transplant 2008; 8: 1744-1748
7. Kamar N, Abravanel F, Selves J et al. Influence of immunosuppres- sive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010; 89: 353-360
8. Kamar N, Rostaing L, Abravanel F et al. Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010; 50: e30-e33
9. Bedossa P, Poynard T. The METAVIR Cooperative Study Group: An algorithm for the grading ofactivity in chronic hepatitis C. Hepatology 1996; 24: 289-293
10. Haagsma EB, van den Berg AP, Porte RJ et al. Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 2008; 14: 547-553
11. Ayaz C, Celen MK, Yuce UN et al. Efficacy and safety of pegylated- interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J Gastroenterol 2008; 14: 255-259
12. van Leusen R, Adang RP, de Vries RA et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008; 23: 721-725
13. Liu CH, Liang CC, Lin JW et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 2008; 57: 525-530
14. le Coutre P, Meisel H, Hofmann J et al. Reactivation of hepatitis E infection in a patient with acute lymphoblastic leukaemia after allo- geneic stem cell transplantation. Gut 2009; 58: 699-702
15. Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098
16. Nicot F, Kamar N, Mariame B et al. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 2010; In press
17. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; S1-S99
18. Ucmak H, Kokoglu OF, Hosoglu S et al. Long-term efficacy of pe- gylated interferon alpha-2a in HCV-positive hemodialysis patients. Ren Fail 2008; 30: 227-232 (Pubitemid 351311488)
19. Weclawiack H, Kamar N, Mehrenberger M et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008; 23: 1043-1047